Human medicines European public assessment report EPAR Solymbic adalimumab Arthritis PsoriaticSpondylitis AnkylosingCrohn DiseaseColitis UlcerativeHidradenitis SuppurativaPsoriasisArthritis Rheumatoid Date of authorisation 22032017 Rev

Human medicines European public assessment report EPAR Solymbic adalimumab Arthritis PsoriaticSpondylitis AnkylosingCrohn DiseaseColitis UlcerativeHidradenitis SuppurativaPsoriasisArthritis Rheumatoid Date of authorisation 22032017 Revision 2 Status Withdr...